Lead Compounds Sample Clauses

The 'Lead Compounds' clause defines which chemical compounds are designated as the primary focus for research, development, or commercialization within an agreement. Typically, this clause specifies the criteria for selecting lead compounds, outlines the process for their identification, and may set forth the rights and obligations of each party regarding their use or further development. By clearly identifying lead compounds, this clause ensures that both parties understand which substances are prioritized, thereby reducing ambiguity and potential disputes over intellectual property or development responsibilities.
Lead Compounds. (a) For each Target, Pharmacopeia will endeavor to identify those Pharmacopeia Compounds that meet the criteria set forth in Table 1. The Lead Compound criteria in Table 1 shall apply uniformly on a Target-by-Target basis. If the characteristics of the Proposed Target warrant it, the criteria in Table 1 may be amended by the JRC to accommodate such characteristics, provided, however, that on balance the set of criteria for any Lead Compound for a Proposed Target shall not be made more stringent than the criteria set forth in Table 1. In addition, the JRC will determine which criteria are considered to be essential and which criteria need to be substantially met. For those criteria that need to be substantially met, the JRC will define the boundaries within which certain material characteristics of a Lead Compound at least should fall. It is understood by both Parties that the boundaries of one of the criteria might depend on the other criteria. The Parties agree that if a Pharmacopeia Compound meets all the criteria set forth in Table 1 (as it may have been amended by the JRC), such Pharmacopeia Compound shall be automatically designated as a “Lead Compound.” Without limitation of the foregoing, the JRC may, at any time, review the progress of the Research Collaboration. In such an event, the JRC may determine that, with respect to any Pharmacopeia Compound, the Research Collaboration with respect to such Pharmacopeia Compound has, notwithstanding the express criteria set forth in Table 1, on balance achieved a stage of development consistent with such criteria, and therefore, such Pharmacopeia Compound shall be designated as a Lead Compound. *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** (b) On an on-going basis, throughout the Research Term, Pharmacopeia shall conduct screening of its Libraries and optimization efforts to identify Pharmacopeia Compounds that have the potential to meet the criteria for a Lead Compound (each such Pharmacopeia Compound a “Potential Lead Compound”). On an on-going basis, Organon shall ***. To enable Organon to ***. The *** and for no other purpose. Following the receipt of a *** for any purpose except as set forth herein. Organon shall ***. The Parties agree that if Organon is unable to provide ***. If no ***. On an as needed basis, the Parties may agree on a commercially reasonable set of additional activities to be carried by either or both Parties to enable the designation of one or more s...
View SourceView Similar (3)
Lead Compounds. ARCHEMIX shall use Commercially Reasonable Efforts in good faith to perform the SELEX® Process to identify Lead Compounds in accordance with each Annual Research Plan, as amended.
View SourceView Similar (2)
Lead Compounds. ARCHEMIX shall use Commercially Reasonable Efforts in good faith to perform the SELEX Process to identify Lead Compounds for the MERCK Funded Program Targets or, as applicable, the MERCK Internal Program Targets or Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. any ARCHEMIX Internal Program Target for which MERCK has provided an Additional Research Request and paid the applicable [***], in accordance with each Annual Research Plan, as amended.
View SourceView Similar (2)
Lead Compounds. Within [***] days after its receipt of each report from ARCHEMIX identifying a Collaboration Compound or IL-23 Aptamer which ARCHEMIX reasonably believes meets the applicable LSC (or which ARCHEMIX otherwise reasonably believes should be a Lead Compound), the JPT shall review the data and information and determine whether to nominate the Collaboration Compound or IL-23 Aptamer for designation by ELAN as a Lead Compound. Once the JPT has reached a decision regarding nomination of any such Collaboration Compound or IL-23 Aptamer as a Lead Compound, the JPT shall promptly furnish all available information to ELAN. ELAN shall consider such nomination within [***] days, and if ELAN determines that the Collaboration Compound or IL-23 Aptamer meets the LSC or is otherwise acceptable and so advises ARCHEMIX in writing, such Collaboration Compound or IL-23 Aptamer shall be designated a “Lead Compound” for purposes of this Agreement. As of the Effective Date, the ARC2350 Aptamer shall be deemed to be a Lead Compound.
View SourceView Similar (2)
Lead Compounds. Notwithstanding any provision of this Agreement, if a Compound is not designated as a Development Candidate within two (2) years following its designation by the JSC as a Lead Compound, such Lead Compound shall cease to be
View SourceView Similar (2)
Lead Compounds. During the Research Term, the JRC will regularly assess the progress of Compounds towards achieving the Lead Compound Criteria. Upon determination by the JRC that a Compound satisfies the Lead Compound Criteria, Biogen Idec will have the right to designate such Compound as a Lead Compound at any time during the Research Term. CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
View SourceView Similar (2)
Lead Compounds. Lead Compounds shall mean not more than two Compounds for which a Testing Request is delivered, which meet the following criteria, as evidenced in writing signed by the Parties: (i) the Compound(s) have been selected by CFFT, as relevant to the Testing Request; (ii) each Compound will be representative of those Compounds in which CombinatoRx believes to be the most promising as a Clinical Development Candidate; and (iii) each Compound shall have been previously tested by CombinatoRx, in vitro, as to potential efficacy and potency in CF, and the results of that testing shall have been provided to CFFT.
View Source
Lead Compounds. (i) To the extent not previously filed in accordance with Subsection 10.3(a) above, Roche Bioscience shall file and prosecute all patent applications covering Inventions containing claims which cover Lead Compounds or other patentable inventions arising from the Research. Roche Bioscience shall bear all Patent Costs of filing, prosecuting and maintaining such Lead Compound Patents. Roche Bioscience shall maintain all Patents that issue on such applications. (ii) Roche Bioscience shall provide Alanex with drafts of any patent application covering Lead Compounds prior to filing that application, allowing adequate time for review and comment by Alanex if possible; provided, however, that Roche Bioscience shall not be obligated to delay the filing of any patent application. Alanex shall maintain any such patent application in confidence, pursuant to Section 11. (iii) If Roche Bioscience decides on a world-wide basis, at any time, not to file or maintain an application on all Lead Compound Patents as provided hereunder, it shall give Alanex notice to this effect and upon such notice Alanex shall have the right, but not the obligation, to file and maintain, such applications or Patents, in its own name and at its own expense, and, if it so elects to file and maintain, Roche Bioscience shall assign to such other Party the rights in such applications or Patents.
View Source
Lead Compounds. The Novartis Disease Area Decision Board, or a decision board of similar function, will select certain Validated Hit Compounds for follow-up under the designation “Research Phase D3 or Lead Optimization” in accordance with the standard drug development criteria used by Novartis. The basic criteria of such designation includes such things as the demonstration of: (1) in vitro potency; (2) specific binding; (3) in vitro selectivity; (4) patentability; (5) chemical feasibility for derivatisation; (6) physico-chemical properties; (7) in vitro PK; (8)in vitro toxicology and (9) in vivo PK. Each Validated Hit Compound which Novartis selects for follow-up under the designation “Research Phase D3 or Lead Optimization” shall hereinafter be referred to as a “Lead Compound.” For clarification, a collection of Lead Compounds with similar chemical structure shall be treated as one Lead Compound for the purposes of this Agreement.
View Source

Related to Lead Compounds

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Research Collaboration Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.

  • Research Program The term “

  • Collaboration activities 4.1 The Collaboration Suppliers will perform the Collaboration Activities and all other obligations of this Agreement in accordance with the Detailed Collaboration Plan. 4.2 The Collaboration Suppliers will provide all additional cooperation and assistance as is reasonably required by the Buyer to ensure the continuous delivery of the services under the Call-Off Contract. 4.3 The Collaboration Suppliers will ensure that their respective subcontractors provide all cooperation and assistance as set out in the Detailed Collaboration Plan.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.